Compounds for FXR Modulation Activity and Uses Thereof - Patent application

Abstract

The present invention provides compounds for modulating the activity of FXR having the structure of formula (I), a pharmaceutically acceptable salt thereof, an ester thereof, or a stereoisomer thereof. [Formula 1] JPEG2023505205000100.jpg68170

Description

Detailed Description of the Invention

[0001] [Technical field] The present invention relates to the medical field related to FXR-mediated diseases. Specifically, the present invention relates to compounds for regulating the activity of FXR, their preparation methods and their medical uses.

[0002] [Background technology] The farnesoid X receptor (FXR) is a member of the nuclear hormone receptor superfamily and is predominantly expressed in the liver, kidney, and intestine. FXR functions as a heterodimer with the retinoid X receptor (RXR) to bind to response elements in the promoters of target genes and regulate gene transcription. The FXR-RXR heterodimer binds with highest affinity to the inverted repeat-1 (IR-1) response element, where the consensus receptor-binding hexamers are separated by one nucleotide. FXR is part of an interrelated process in which FXR is activated by bile acids (the end products of cholesterol metabolism), which in turn acts to inhibit cholesterol catabolism.

[0003] FXR is a key regulator of cholesterol homeostasis, triglyceride synthesis, and lipogenesis (Crawley, Expert Opinion Ther. Patents (2010), 20(8):1047-1057). In addition to dyslipidemia, obesity, vitamin D-related diseases, enteropathy, drug-induced side effects, and hepatitis, FXR-related conditions include hepatobiliary diseases, chronic hepatitis, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), cholestasis, liver fibrosis, cirrhosis, hepatitis B, metabolic diseases, lipid metabolic diseases, carbohydrate metabolic diseases, cardiometabolic diseases, atherosclerosis, type II diabetes and diabetic complications.

[0004] A variety of compounds capable of acting as FXR modulators (or FXR-agonists) have been developed, including, for example, the small molecule FXR modulators described in WO200037077, WO2003 / 015771, WO2004 / 048349, WO2007 / 076260, WO2007 / 092751, WO2007 / 140174, WO2007 / 140183, as well as the small molecule FXR modulators described in WO20 08 / 051942, WO2008 / 157270, WO2009 / 005998, WO2009 / 012125, WO2009 / 149795, WO2008 / 025539, WO2008 / 025540, WO2012 / 087520, WO2012 / 087521, WO2012 / 087519, and WO2015 / 036442. Although some progress has been made in the development of novel FXR agonists, significant room remains for improving FXR agonists.

[0005] [Disclosure of the Invention] The object of the present invention is to provide novel compounds for use as FXR agonists, which have excellent physicochemical, in vitro and / or in vivo ADME (adsorption, distribution, metabolism and excretion) properties, and excellent pharmacokinetics, and reduced side effects, methods for their preparation, and pharmaceutical uses thereof.

[0006] [Definition] For the purposes of interpreting this specification, the following definitions will apply and whenever appropriate, terms used in the singular will also include the plural and vice versa.

[0007] As used herein, the term "C 1~6"Alkyl" means an alkyl radical having 1 up to 6, especially up to 4, carbon atoms, which radical is either straight-chained or branched with single or multiple branches, for example, butyl, e.g., n-butyl, sec-butyl, isobutyl, tert-butyl, etc.; propyl, e.g., n-propyl or isopropyl, etc.; ethyl or methyl; more specifically, methyl, isopropyl or tert-butyl.

[0008] As used herein, "C 1~6 Alkoxy is "C 1~6 "alkyl-O-" and in particular methoxy, ethoxy, isopropyloxy, or tert-butoxy.

[0009] As used herein, the term "C 3~6 "Cycloalkyl" refers to a cyclic alkyl radical having 3 to 6 carbon atoms, e.g., cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. 3~6 Cycloalkyl is C 1~6 It can be optionally substituted with alkyl and / or halogen.

[0010] As used herein, the term "C 4~7 "Alkylcycloalkyl" refers to a combination of an alkyl group and a cycloalkyl group having a total of 4 to 7 carbon atoms. For example, C4 alkylcycloalkyl includes methylenecyclopropyl.

[0011] As used herein, the term "5-10 membered aryl" refers to a 5-10 membered monocyclic, bicyclic or tricyclic aromatic ring system. Typically, the aryl is a 5- or 6-membered ring system.

[0012] As used herein, the term "5-10 membered heteroaryl" refers to a 5-10 membered monocyclic, bicyclic or tricyclic aromatic ring system having 1 to 4 heteroatoms. Typically, the heteroaryl is a 5-membered or 6-membered ring system. Furthermore, as used herein, the term "heteroaryl" can include monovalent or divalent heteroaryl.

[0013] As used herein, the terms "halogen" or "halo" refer to one or more of fluoro, chloro, bromo and iodo, and more specifically refer to fluoro or chloro.

[0014] As used herein, the term "C 1~6 "Haloalkyl" refers to an alkyl radical that is substituted by one or more halo radicals, specifically, C 1~6 Fluoroalkyl or C 1~6 Chloroalkyl, such as trifluoromethyl and 2,2,2-trifluoroethyl.

[0015] As used herein, the term "pharmaceutically acceptable auxiliary material" may include any or all solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial and antifungal agents), isotonic agents, absorption delaying agents, salts, drug stabilizers, binders, excipients, disintegrants, lubricants, sweeteners, flavoring agents, dyes, and the like, and combinations thereof, as known to those skilled in the art. Except in the case of a carrier which is incompatible with the active ingredient, any conventional carrier is contemplated for use in the therapeutic or pharmaceutical compositions.

[0016] As used herein, the term "therapeutically effective amount" refers to the amount of the compound of formula (I) that is sufficient to achieve the described therapeutic effect. Thus, the therapeutically effective amount of the compound of formula (I) used for treating a condition mediated by FXR will be an amount sufficient to treat the condition mediated by FXR.

[0017] In one aspect, the present invention provides a compound for modulating the activity of FXR having the structure of formula (I), a pharma- ceutically acceptable salt thereof, an ester thereof, or a stereoisomer thereof:

[0018] [ka]

[0019] During the ceremony: R 1 , R 2 and R 3 is H, halogen, unsubstituted or halogen-substituted C 1~6 Alkyl, and unsubstituted or halogen-substituted C 1~6 alkoxy, where R 1 , R 2 , and R 3 provided that at least one of R 0 is unsubstituted or halogen-substituted C 1~6 Alkyl, C 3~6 Cycloalkyl, C 4~7 alkylcycloalkyl; X 1 and X 2 is independently selected from H and a halogen; The moiety -OZ (residue Z linked to the naphthalene ring via an oxygen atom) is attached to the naphthalene ring, where Z is a residue selected from 5-10 membered aryl or 5-10 membered heteroaryl, optionally having one or more heteroatoms selected from N, O, and S, where the 5-10 membered aryl or 5-10 membered heteroaryl is selected from R 4 and optionally R 5 is further replaced by; Here, R 4 -COOH, -CH2COOH, -NHSO2CF3, -SO2NH-C 1~6 Alkyl, -SO3H, -CONHSO2-C 1~6 Alkyl, -CONHSO2-C 3~6Cycloalkyl, -CONHSO2-5 to 10-membered aryl, and C in aryl 1~6 R is selected from -CONHSO2-5 to 10 membered aryl substituted by alkyl; 5 , H, C 1~6 Alkyl, halogen, C 1~6 Haloalkyl, -O-(C 1~6 alkyl), and -NH-(C 1~6 alkyl).

[0020] In a preferred embodiment of the present invention, R 1 , R 2 and R 3 H, halogens and C 1~3 perfluoroalkoxy, e.g., H, Cl, F, and -O-CF3. In one embodiment of the present invention, R 1 and R 2 are Cl, and R 3 is H. In another embodiment of the present invention, R 1 and R 2 are Cl, and R 3 is F. In yet another embodiment of the present invention, R 1 and R 2 are Cl, and R 3 is -O-CH3. In yet another embodiment of the present invention, R 1 is -O-CF3, R 2 and R 3 and R are H. In yet another embodiment of the present invention, 0 is isopropyl or cyclopropyl.

[0021] In one embodiment of the present invention, Z is phenyl, optionally substituted with 1 to 5 halogen atoms. In another embodiment of the present invention, Z is a 5 to 10 membered heteroaryl having one or more heteroatoms selected from N, O, and S. In a preferred embodiment of the present invention, Z is a 5 to 6 membered heteroaryl having one or more heteroatoms selected from N, O, and S. In yet another embodiment of the present invention, Z is R4 and optionally R 5 It is a substituted pyridyl.

[0022] In a preferred embodiment of the present invention, R 4 -COOH, -CH2COOH, -CONHSO2-C 1~6 Alkyl, and -CONHSO2-C 3~6 In a more preferred embodiment of the present invention, R 4 is -COOH or -CHCOOH. In the most preferred embodiment of the present invention, R 4 is -COOH.

[0023] Preferably, R 5 , H, C 1~3 The aryl group is one selected from alkyl, alkyl, and halogen. In a preferred embodiment of the invention, Z is pyridyl; R 4 is -COOH; R 5 is H or a halogen.

[0024] Preferably, the halogen in said substituents is fluoro or chloro. Specifically, in a preferred embodiment of the invention, the compound having formula (I) has the following structure:

[0025] [ka]

[0026] [ka]

[0027] [ka]

[0028] [ka]

[0029] [ka] It is one of them.

[0030] In another aspect, the present invention provides methods for preparing a compound of formula (I), a pharma- ceutically acceptable salt thereof, an ester thereof, or a stereoisomer thereof, the methods including four general routes (Route A, Route B, Route C, and Route D): Route A:

[0031] [ka]

[0032] Route B:

[0033] [ka]

[0034] Route C:

[0035] [ka]

[0036] Route D:

[0037] [ka]

[0038] The four general routes are described in detail below. Route A: (a) reacting a halogenated compound of formula (A1) with a dinaphthol to obtain an ether of formula (A2), the reaction being carried out in a polar solvent with a base, preferably in DMF or acetonitrile with cesium or potassium carbonate, or a similar base, or the like.

[0039] where: X is a halogen; R 1 , R 2 and R 3 is H, halogen, unsubstituted or halogen-substituted C 1~6 Alkyl, and unsubstituted or halogen-substituted C 1~6 alkoxy, where R 1 , R 2 , and R 3 provided that at least one of R 0 is unsubstituted or halogen-substituted C 1~6 Alkyl, C 3~6 Cycloalkyl, and C 4~7 alkylcycloalkyl; (b) reacting the obtained ether of formula (A2) with a halogenated compound XZ to obtain a compound of formula (I); where X is a halogen and Z is a residue selected from 5-10 membered heteroaryl having one or more heteroatoms selected from N, O, and S, where the residue Z is R 4 and optionally R 5 is further replaced by; Here, R 4 -COOH, -CH2COOH, -NHSO2CF3, -SO2NH-C 1~6 Alkyl, -SO3H, -CONHSO2-C 1~6 Alkyl, -CONHSO2-C 3~6 Cycloalkyl, -CONHSO2- 5~10 aryl and C in the aryl group 1~6 R is selected from -CONHSO2-5 to 10 membered aryl substituted by alkyl; 5 , H, C1~6 Alkyl, halogen, and C 1~6 haloalkyl; optionally (c) reacting a compound of formula (I) containing a -COOH substituent with an amide compound to obtain an amide compound of the compound of formula (I); and optionally (d) R where Z is selected from -COOH and -CHCOOH 4 When substituted with, the ester precursor can be converted to the free acid by hydrolysis using conditions well known to those skilled in the art, wherein the compound of formula (I) is as defined above. According to the preparation method provided by the present invention, X is preferably bromine or iodine, more preferably bromine.

[0040] Route B: (a) reacting a halogenated compound of formula (A1) with a substituted naphthol (B1) to obtain an ether of formula (B2), the reaction being carried out in a polar solvent with a base, preferably in DMF or acetonitrile with cesium or potassium carbonate, or a similar base, or the like; (b) converting compound (B2) to a boronic ester of formula (B3), preferably under Pd catalyzed conditions; (c) converting compound (B3) to naphthol (A2) by oxidation with an oxidizing agent such as NaClO2 or H2O2; (d) converting compound (A2) to compound (I) using the conditions outlined in Route A; Where X 3 is a halogen, preferably bromine or iodine, more preferably bromine.

[0041] Route C: (a) reacting a substituted naphthol (C1) with a halogenated compound XZ to obtain an ether of formula (C2), wherein the reaction is carried out in a polar solvent with a base, preferably in DMF or acetonitrile with cesium carbonate, potassium carbonate, or a similar base, or the like; (b) converting compound (C2) to a boronic ester (C3), preferably under Pd-catalyzed conditions; (c) converting compound (C3) to naphthol (C4) by oxidation with an oxidizing agent such as NaClO2 or H2O2; (d) converting compound (C4) to compound (I) using conditions similar to those outlined in Route A; Where X 4 is a halogen, preferably bromine or iodine, more preferably bromine.

[0042] Route D: (a) reacting a dinaphthol with a halogenated compound XZ to give an ether of formula (C4) using conditions similar to those outlined in Route C; (b) Compound (C4) is converted to compound (I) using similar conditions as outlined in Route C.

[0043] In yet another aspect, the present invention provides a pharmaceutical composition comprising a compound of formula (I), or a prodrug compound thereof, or a pharma- ceutically acceptable salt thereof, an ester thereof, or a stereoisomer thereof, and a pharma- ceutically acceptable auxiliary material.

[0044] The pharmaceutical compositions of the present invention may further comprise one or more other active compounds having additional therapeutic effects. The pharmaceutical compositions are suitable for oral, rectal, topical, parenteral (including subcutaneous, intramuscular, and intravenous), ocular (ophthalmic), pulmonary (nasal or oral inhalation) or nasal administration, although the most suitable route in any given case will depend on the nature and severity of the condition being treated and on the nature of the active ingredient. The pharmaceutical compositions may conveniently be presented in unit dosage form and may be prepared by any of the methods well known to those skilled in the art of pharmacy.

[0045] The compounds of formula (I) and their pharmacologic acceptable salts show valuable pharmacological properties when tested in in vitro binding assays and cellular assays, and are therefore useful as pharmaceuticals.Specifically, the compounds of the present invention are agonists of FXR, and are useful as pharmaceuticals for treating FXR-mediated conditions, such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis (PBC), cholestatic liver disease, chronic liver disease, hepatitis C infection, alcoholic liver disease, liver fibrosis, primary sclerosing cholangitis (PSC), gallstones, biliary atresia, lower urinary tract symptoms and benign prostatic hyperplasia (BPH), ureteral stones, obesity, type 2 diabetes, atherosclerosis, hypercholesterolemia and dyslipidemia-induced liver damage, etc. The compounds of the invention are also useful for lowering total cholesterol, lowering LDL cholesterol, lowering VLDL cholesterol, increasing HDL levels, and / or lowering triglyceride levels.

[0046] In yet another aspect, the present invention provides a method for treating, ameliorating, or preventing an FXR mediated disorder in a patient suffering from an FXR mediated disorder, the method comprising administering to the patient a therapeutically effective amount of a compound of formula (I), a pharma- ceutically acceptable salt thereof, a stable isotopic analog thereof, an ester thereof, or a stereoisomer thereof, or a pharmaceutical composition thereof, optionally in combination with a second therapeutic agent. The present invention also provides the use of a compound of formula (I), a pharma- ceutically acceptable salt, an ester, or a stereoisomer thereof, and optionally in combination with a second therapeutic agent, in the manufacture of a medicament for treating an FXR mediated disease, such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis (PBC), cholestatic liver tree, chronic liver disease, hepatitis C infection, alcoholic liver disease, hepatic fibrosis, primary sclerosing cholangitis (PSC), gallstones, biliary atresia, lower urinary tract symptoms and benign prostatic hyperplasia (BPH), ureteral stones, liver damage caused by obesity, type 2 diabetes, atherosclerosis, hypercholesterolemia or dyslipidemia.

[0047] Unless otherwise specified, the term "compounds of the invention" refers to compounds of formula (I), prodrugs thereof, salts of the compounds of formula (I) and / or the prodrugs, hydrates or solvates of the compounds of formula (I), and all stereoisomers (diastereoisomers and enantiomers), tautomers, isotopically labeled compounds (including deuterium substitutions) and polymorphs of the compounds.

[0048] Salts of the compounds of the present invention may be prepared by methods known to those of ordinary skill in the art, for example, treating a compound of the present invention with an appropriate base or acid in an appropriate solvent will yield the corresponding salt.

[0049] The salts included in the term "pharmaceutically acceptable salts" refer to non-toxic salts of the compounds of the present invention.Preferably, alkali salts of carboxylic acids, such as sodium, potassium, lithium, calcium, magnesium, aluminum, zinc, N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, N-methylglucamine and procaine salts.Other salts that are not pharmaceutically acceptable may be useful in the preparation of the compounds of the present invention, and these should be considered as forming a further aspect of the present invention.

[0050] All starting materials, reagents, acids, bases, solvents and catalysts utilized to synthesize the compounds of the present invention are either commercially available or can be produced by organic synthesis methods known to those skilled in the art. All methods described herein can be carried out in any suitable order unless otherwise indicated herein or clearly contradicted by context. Any and all examples provided herein, or the use of exemplary language (such as, for example, etc.) are merely intended to better clarify the invention and do not pose limitations on the scope of the invention as otherwise claimed. [Brief description of the drawings]

[0051] In order to more clearly describe the embodiments of the present invention or the technical solutions of the prior art, the drawings necessary for describing the embodiments of the present invention are briefly described below. It should be understood that the drawings in the following description are only some embodiments of the present invention.

[0052] [Figure 1] FIG. 1 shows the reduction in NAS scores following treatment with Compound 1 in a streptozocin (STZ) + diethylnitrosamine (DEN) + high fat diet (HFD) mouse disease model. [Diagram 2] FIG. 2 shows reduction of liver fibrosis following Compound 1 treatment in the STZ+DEN+HFD mouse disease model. [Diagram 3]FIG. 3 shows the reduction in NAS scores after Compound 1 treatment in diethylnitrosamine (DEN)+high fat diet (HFD)+cholesterol / cholate (CHOL) treated rats. [Figure 4] FIG. 4 shows the reduction of liver fibrosis after Compound 1 treatment in DEN+HFD+CHOL treated rats. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0053] [Best Mode for Carrying Out the Invention] The present invention will be further described with reference to the following examples. It should be noted that the following examples are only for illustration, and are not for the limitation of the present invention. Various modifications made by those skilled in the art according to the teachings of the present invention should be within the scope of the present invention.

[0054] [Example 1] Preparation of 6-((6-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)naphthalen-2-yl)oxy)nicotinic acid (compound 1)

[0055] [ka]

[0056] (a) For the following reaction scheme (Route A), compound 1A-1 (1.0 g, 2.88 mmol, 1 eq.), compound 1A-2 (0.46 g, 2.88 mmol, 1 eq.) and cesium carbonate (1.88 g, 5.76 mmol, 2 eq.) were dissolved in DMF (10 ml). The reaction was carried out at 65° C. for 2 hours. After cooling, 10 ml of water and 10 ml of EA (ethyl acetate) were added for extraction, and the organic phase was washed with water and concentrated to dryness to obtain compound 1A, 6-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)naphthalen-2-ol, 0.8 g, yield: 65.0%. LCMS (ESI): C 23 H 17C l2 Calculated for NO3; [M+H] + :426.1,Actual value:426.1.

[0057] [ka]

[0058] (b) For the following reaction scheme, compound 1A (0.2 g, 0.47 mmol, 1 eq.), 6-bromonicotinic acid methyl ester (0.1 g, 0.47 mmol, 1 eq.) and cesium carbonate (0.306 g, 0.94 mmol, 2 eq.) were dissolved in DMF (10 ml). The reaction was carried out at 65° C. for 2 h. After cooling, 10 ml of water and 10 ml of EA were added for extraction, and the organic phase was washed with water and concentrated to dryness to give compound 1B, methyl 6-((6-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)naphthalen-2-yl)oxy)nicotinate, 0.21 g, yield: 80.0%. LCMS (ESI): C 30 H 22 C l2 Calculated for N2O5; [M+H] + :561.1,Actual value:561.1.

[0059] [ka]

[0060] (c) For the following reaction scheme, compound 1B (100 mg) was dissolved in methanol (2 ml), then 10% NaOH aqueous solution (1 ml) was added, the temperature was raised to 60° C., and the reaction was carried out for 1 hour. The pH of the reaction solution was adjusted from pH 2 to pH 4 by adding 1N HCl solution, and 10 ml of EA (ethyl acetate) was added for extraction. The organic phase was concentrated and purified by column (PE / EA / AcOH=1 / 1 / 0.01 eluent, where PE is petroleum ether) to obtain the title compound 1 (36 mg, yield: 37.0%).

[0061] 1HNMR(400MHz,DMSO-d6)δ8.57(s,1H),8.23(d,J=7.2Hz,1H),7.74(dd,J=2.0,8.8Hz,2H),7.60(d,J=7.6Hz,2H),7.56(s,1H),7.51(dd,J=8.8,7 .2Hz,1H),7.33(s,1H),7.26(d,J=8.8Hz,1H),7.02(d,J=8.0Hz,1H),6. 93(d,J=6.4Hz,1H),4.98(s,2H),2.57-2.50(m,1H),1.19-1.11(m,4H). LCMS(ESI):C 29 H 20 Calculated for Cl2N2O5; [M+H] + :547.1,Actual value:547.1. 13 CNMR(400MHz,DMSO-d6)δ7.79,8.87,8.87,59.31,107.74,110.05,110.97,117.64,119.43,122.52,127.55,128.64,128.89,128 .89,129.18,129.67,131.73,131.79,132.94,135.10,135.10,141.20,149.11,150.73,155.79,159.68,163.82,167.81,172.61. IR(cm -1 ):Main stretch at 1591.94 (C=O stretch), 1412.27, 1556.70 (C-C stretch), 1364.37, 1389.89 (CH bending), 1218.41, 1250.94 (C=N stretch), 791.88 (C-Cl stretch).

[0062] [ka]

[0063] [Example 2] Preparation of 6-((6-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)naphthalen-2-yl)oxy)pyridazine-3-carboxylic acid (compound 2)

[0064] [ka]

[0065] Following the procedure of Example 1, the title compound 2 was obtained by substituting 6-bromopyridazine-3-carboxylate methyl ester for 6-bromonicotinic acid methyl ester.

[0066] 1 HNMR(400MHz,DMSO-d6)δ8.52(s,1H),8.25(d,J=7.2Hz,1H),7.74(dd,J=2.0,8.8Hz,2H),7.61(d,J=7.6Hz,2H),7.52(dd,J=8.8,7.2Hz, 1H),7.34(s,1H),7.26(d,J=8.8Hz,1H),7.00(d,J=8.0Hz,1H),6.95(d,J=6.4Hz,1H),4.98(s,2H),2.59-2.50(m,1H),1.21-1.11(m,4H). LCMS(ESI):C 28 H 19 Calculated for Cl2N3O5; [M+H] + :548.1,Actual value:548.1.

[0067] [Example 3] Preparation of 5-chloro-6-((6-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)naphthalen-2-yl)oxy)nicotinic acid (compound 3)

[0068] [ka]

[0069] Following the procedure of Example 1, the title compound 3 was obtained by substituting methyl 5,6-dichloronicotinate for 6-bromonicotinic acid methyl ester.

[0070] 1HNMR(400MHz,DMSO-d6)δ8.60(s,1H),7.73(dd,J=2.0,8.8Hz,2H),7.59(d,J=7.6Hz,2H),7.51(dd,J=8.8,7.2Hz,1H ),7.33(s,1H),7.26(d,J=8.8Hz,1H),7.01(d,J=8.0Hz,1H),6.95(d,J=6.4Hz,1H),5.00(s,2H),1.26-1.12(m,5H). LCMS(ESI):C 29 H 19 Calculated for Cl3N2O5; [M+H] + :581.0,Actual value:581.0.

[0071] [Example 4] Preparation of 2-((6-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)naphthalen-2-yl)oxy)thiazole-5-carboxylic acid (compound 4)

[0072] [ka]

[0073] Following the procedure of Example 1, the title compound 4 was obtained by substituting 2-bromothiazole-5-carboxylate methyl ester for 6-bromonicotinic acid methyl ester.

[0074] 1 HNMR(400MHz,DMSO-d6)δ8.80(s,1H),7.69(dd,J=2.0,8.8 Hz,2H),7.59(d,J=7.6Hz,2H),7.53(dd,J=8.8,7.2Hz,1H),7.32(s,1H),7.26(d,J=8. 8Hz,1H),7.01(d,J=8.0Hz,1H),6.99(d,J=6.4Hz,1H),5.00(s,2H),1.25-1.12(m,5H). LCMS(ESI):C 27 H 18 Calculated for Cl2N2O5S; [M+H] + :553.0,Actual value:553.0.

[0075] [Example 5] Preparation of 6-((6-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)naphthalen-2-yl)oxy)-5-methylnicotinic acid (compound 5)

[0076] [ka]

[0077] Following the procedure of Example 1, the title compound 5 was obtained by substituting methyl 6-bromo-5-methylnicotinate for 6-bromonicotinic acid methyl ester.

[0078] 1 HNMR(400MHz,DMSO-d6)δ12.78(s,1H),8.35(d,J=1.5Hz,1H),8.12-7.90(m,1H),7.72-7.61(m,2H),7.54(s,3H),7.28(m,2H),7.15-7 .10(m,1H),7.07(dd,J=7.5,1.5Hz,1H),6.95(dd,J=7.6,1.6Hz,1H),5.41(s,2H),2.99-2.70(m,1H),2.28(s,3H),2.12-1.56(m,4H). LCMS(ESI):C 30 H 22 Calculated for Cl2N2O5; [M+H] + :561.1,Actual value:561.1.

[0079] [Example 6] Preparation of 6-((6-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)naphthalen-2-yl)oxy)-N-(cyclopropylsulfonyl)nicotinamide (compound 6)

[0080] [ka]

[0081] Compound 1 (70 mg) prepared in Example 1 and cyclopropylsulfonamide (23 mg) were dissolved in 2 ml of DCM (dichloromethane), then 40 mg of EDCI (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride) and 26 mg of DMAP (dimethylaminopyridine) were added. After completion of the reaction, 10 ml of DCM and 10 ml of water were added for extraction. The organic phase was washed with water and concentrated to dryness. The crude product was purified by column (PE / EA / AcOH=2 / 1 / 0.01) to obtain the title compound 6 (8 mg, yield: 9.6%).

[0082] 1 HNMR(400MHz,DMSO-d6)δ8.63(d,J=1.5Hz,1H),8.30(dd,J=7.5,1.5Hz,1H),7.79(d,J=8.0Hz,1H),7.73(d,J=8.0Hz,1H),7.59-7.62( m,3H),7.49-7.53(m,1H),7.35(s,1H),7.26-7.29(m,1H),7.10(d,J=8.0Hz,1H),6.93-6.96(m,1H),4.98(s,2H),1.02-1.20(m,10H). LCMS(ESI):C 32 H 25 Calculated for Cl2N3O6S; [M+H] + :650.1,Actual value:650.1.

[0083] [Example 7] Preparation of 5-((6-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)naphthalen-2-yl)oxy)pyrazine-2-carboxylic acid (compound 7)

[0084] [ka]

[0085] Following the procedure of Example 1, the title compound 7 was obtained by substituting methyl 5-chloro-pyridine-2-carboxylate for 6-bromonicotinic acid methyl ester.

[0086] 1 HNMR(400MHz,DMSO-d6)δ8.63(s,1H),8.30(s,1H),7.79(d,J=8.8Hz,1H),7.72(d,J=9.2Hz,1H),7.58-7.6 3(m,4H),7.49-7.53(m,1H),7.34(d,J=2.0Hz,1H),6.94(d,J=9.2Hz,1H),4.98(s,2H),1.11-1.22(m,5H). LCMS(ESI):C 28 H 19 Calculated for Cl2N3O5; [M+H] + :548.1,Actual value:548.1.

[0087] [Example 8] Preparation of 2-chloro-6-((6-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)naphthalen-2-yl)oxy)nicotinic acid (compound 8)

[0088] [ka]

[0089] Following the procedure of Example 1, the title compound 8 was obtained by substituting methyl 2,6-dichloronicotinate for 6-bromonicotinic acid methyl ester. 1 HNMR(400MHz,DMSO-d6)δ7.98(br s,1H),7.70-7.79(m,2H),7.60(d,J=8.0Hz,2H),7.47-7.55(m,2H),7.18-7.33(m,2H),6.90-6.95(m,2H),4.98(s,2H),1.11-1.22(m,5H). LCMS(ESI):C 29 H 19 Calculated for Cl3N2O5; [M+H] + :581.0,Actual value:581.0.

[0090] [Example 9] Preparation of 5-((6-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)naphthalen-2-yl)oxy)picolinic acid (compound 9)

[0091] [ka]

[0092] Following the procedure of Example 1, the title compound 9 was obtained by substituting methyl 5-bromopicolinate for 6-bromonicotinic acid methyl ester. 1 HNMR(400MHz,DMSO-d6)δ8.46(d,J=3.1Hz,1H),8.03(d,J=8.7Hz,1H),7.83(d,J=8.9Hz,1H),7.72(d,J=9.1Hz,1H),7.55 (dt,J=28.7,8.3Hz,4H),7.43(d,J=8.6Hz,1H),7.39-7.24(m,2H),6.95(d,J=8.9Hz,1H),4.98(s,2H),1.23-1.02(m,5H). LCMS(ESI):C 29 H 20 Calculated for Cl2N2O5; [M+H] + :547.1,Actual value:547.1.

[0093] [Example 10] Preparation of 6-((6-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)naphthalen-2-yl)oxy)-2-methylnicotinic acid (compound 10)

[0094] [ka]

[0095] Following the procedure of Example 1, the title compound 10 was obtained by substituting methyl 6-chloro-2-methylnicotinate for 6-bromonicotinic acid methyl ester.

[0096] 1 HNMR(400MHz,DMSO-d6)δ8.21(d,J=8.6Hz,1H),7.78(d,J=8.9Hz,1H),7.72(d,J=9.0Hz,1H),7.62-7.55(m,3H),7.51(dd,J=9.0,7.1Hz,1H),7.3 4(d,J=2.5Hz,1H),7.27(dd,J=8.8,2.4Hz,1H),6.94(dd,J=8.9,2.5Hz,1H),6.85(d,J=8.6Hz,1H),4.98(s,2H),2.52(s,3H),1.24-1.07(m,5H). LCMS(ESI):C 30 H 22 Calculated for Cl2N2O5: [M+H] + :561.1,Actual value:561.1.

[0097] [Example 11] Preparation of 6-((6-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)naphthalen-2-yl)oxy)picolinic acid (compound 11)

[0098] [ka]

[0099] Following the procedure of Example 1, the title compound 11 was obtained by substituting methyl 2,6-dichloronicotinate for 6-bromonicotinic acid methyl ester.

[0100] 1 HNMR(400MHz,DMSO-d6)δ7.99(t,J=7.9Hz,1H),7.77(d,J=8.1Hz,2H),7.71(d,J=8.9Hz,1H),7.63-7.45(m,4H), 7.33(s,1H),7.29(d,J=9.0Hz,1H),7.22(d,J=8.2Hz,1H),6.94(d,J=9.0Hz,1H),4.98(s,2H),1.26-1.01(m,5H). LCMS(ESI):C 29 H 20 Calculated for Cl2N2O5; [M+H] +:547.1,Actual value:547.1.

[0101] [Example 12] Preparation of 2-((6-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)naphthalen-2-yl)oxy)isonicotinic acid (compound 12)

[0102] [ka]

[0103] Following the procedure of Example 1, the title compound 12 was obtained by substituting methyl 2-fluoroisonicotinate for 6-bromonicotinic acid methyl ester.

[0104] 1 HNMR(400MHz,DMSO-d6)δ8.29(d,J=5.1Hz,1H),7.78(d,J=8.8Hz,1H),7.59(t,J=7 .7Hz,3H),7.52(m,2H),7.34(s,2H),7.29(s,1H),4.98(s,2H),1.31-1.06(m,5H). LCMS(ESI):C 29 H 20 Calculated for Cl2N2O5; [M+H] + :547.1,Actual value:547.1.

[0105] [Example 13] Preparation of 3-((6-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)naphthalen-2-yl)oxy)picolinic acid (compound 13)

[0106] [ka]

[0107] Following the procedure of Example 1, the title compound 13 was obtained by substituting methyl 3-fluoropicolinate for 6-bromonicotinic acid methyl ester. 1 HNMR(400MHz,DMSO-d6)δ8.39(d,J=4.4Hz,1H),7.77(d,J=9.0Hz,1H),7.66(d,J=9.2Hz,1H),7.59(d,J=8.1Hz,2H ),7.54-7.43(m,3H),7.30(d,J=2.8Hz,2H),7.26-7.16(m,1H),6.95-6.85(m,1H),4.95(s,2H),1.24-1.06(m,5H). LCMS(ESI):C 29 H 20 Calculated for Cl2N2O5: [M+H] + :547.1,Actual value:547.1.

[0108] [Example 14] Preparation of 2-((6-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)naphthalen-2-yl)oxy)benzoic acid (compound 14)

[0109] [ka]

[0110] Following the procedure of Example 1, the title compound 14 was obtained by substituting methyl 2-fluorobenzoate for 6-bromonicotinic acid methyl ester. 1 HNMR(400MHz,DMSO-d6)δ7.82(d,J=7.8Hz,1H),7.73(d,J=8.9Hz,1H),7.66-7.57(m,3H),7.55-7.45(m ,2H),7.26(d,J=10.6Hz,2H),7.21-7.11(m,2H),6.99(d,J=8.3Hz,1H),4.94(s,2H),1.27-1.06(m,5H). LCMS(ESI):C 30 H 21 Calculated for Cl2NO5; [M+H] + :546.1,Actual value:546.1 [Example 15] Preparation of 2-((6-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)naphthalen-2-yl)oxy)nicotinic acid (compound 15)

[0111] [ka]

[0112] Following the procedure of Example 1, the title compound 15 was obtained by substituting methyl 2-chloronicotinate for 6-bromonicotinic acid methyl ester. 1 HNMR(400MHz,DMSO-d6)δ8.30-8.19(m,2H),7.73(dd,J=19.2,9.0Hz,2H),7.60(d,J=7.9Hz,2H),7.55-7.47( m,2H),7.32(d,J=2.5Hz,1H),7.26-7.18(m,2H),6.92(dd,J=8.9,2.5Hz,1H),4.98(s,2H),1.23-1.10(m,5H). LCMS(ESI):C 29 H 20 Calculated for Cl2N2O5; [M+H] + :547.1,Actual value:547.1.

[0113] [Example 16] Preparation of 3-((6-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)naphthalen-2-yl)oxy)isonicotinic acid (compound 16)

[0114] [ka]

[0115] Following the procedure of Example 1, the title compound 16 was obtained by substituting methyl 3-fluoroisonicotinate for 6-bromonicotinic acid methyl ester.

[0116] 1HNMR(400MHz,DMSO-d6)δ8.52(d,J=4.8Hz,1H),8.39(s,1H),7.76(d,J=8.9Hz,1H),7.73(d,J=4.9Hz,1H),7.64(d,J=9.0Hz,1H),7 .59(d,J=7.7Hz,2H),7.50(dd,J=9.0,7.0Hz,1H),7.32-7.15(m,4H),6.89(dd,J=8.9,2.5Hz,1H),4.95(s,2H),1.27-1.09(m,5H). LCMS(ESI):C 29 H 20 Calculated for Cl2N2O5; [M+H] + :547.1,Actual value:547.1.

[0117] [Example 17] Preparation of 6-((6-((5-cyclopropyl-3-(2-(trifluoromethoxy)phenyl)isoxazol-4-yl)methoxy)naphthalen-2-yl)oxy)nicotinic acid (compound 17)

[0118] [ka]

[0119] Following the procedure of Example 1, the title compound 17 was obtained by substituting 4-(chloromethyl)-5-cyclopropyl-3-(2-(trifluoromethoxy)phenyl)isoxazole for 1A-1.

[0120] 1 HNMR(400MHz,DMSO-d6)δ8.62(s,1H),8.27(d,J=8.1Hz,1H),7.75(dt,J=31.9,15.9Hz,2H),7.61(s,2H),7.56-7.43(m,2H),7.3 6(s,1H),7.29(d,J=8.6Hz,1H),7.11(d,J=8.2Hz,1H),7.00(d,J=8.5Hz,1H),5.03(s,2H),2.44-2.37(m,1H),1.20-1.05(m,4H). LCMS(ESI):C 30 H 21Calculated for F3N2O6; [M+H] + :563.1,Actual value:563.1.

[0121] [Example 18] Preparation of 6-((6-((5-cyclopropyl-3-(2,6-dichloro-4-fluorophenyl)isoxazol-4-yl)methoxy)naphthalen-2-yl)oxy)nicotinic acid (compound 18)

[0122] [ka]

[0123] Following the procedure of Example 1, the title compound 18 was obtained by substituting 4-(chloromethyl)-5-cyclopropyl-3-(2,6-dichloro-4-fluorophenyl)isoxazole for 1A-1.

[0124] 1 HNMR(400MHz,DMSO-d6)δ8.63(s,1H),8.27(d,J=7.9Hz,1H),7.87-7.63(m,4H),7.60(s,1H),7.40-7.24 (m,2H),7.11(d,J=8.0Hz,1H),6.96(d,J=8.6Hz,1H),4.98(s,2H),2.47-2.40(m,1H),1.23-1.08(m,4H). LCMS(ESI):C 29 H 19 Calculated for Cl2FN2O5; [M+H] + :565.1,Actual value:565.1.

[0125] [Example 19] Preparation of 6-((6-((5-cyclopropyl-3-(2,6-dichloro-4-methoxyphenyl)isoxazol-4-yl)methoxy)naphthalen-2-yl)oxy)nicotinic acid (compound 19)

[0126] [ka]

[0127] Following the procedure of Example 1, the title compound 19 was obtained by substituting 4-(chloromethyl)-5-cyclopropyl-3-(2,6-dichloro-4-methoxyphenyl)isoxazole for 1A-1. LCMS(ESI):C 30 H 22 C l2 Calculated for N2O6; [M+H] + :577.1,Actual value:577.1.

[0128] [Example 20] Preparation of 6-((6-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)-1-fluoronaphthalen-2-yl)oxy)nicotinic acid (compound 20)

[0129] [ka]

[0130] (a) For the following reaction scheme (Route C), compound 20A-1 (1.0 g, 4.15 mmol, 1 eq.), compound 20A-2 (0.90 g, 4.15 mmol, 1 eq.) and cesium carbonate (2.70 g, 8.30 mmol, 2 eq.) were dissolved in DMF (10 ml). The reaction was carried out at 65° C. for 2 hours. After cooling, 10 ml of water and 10 ml of EA (ethyl acetate) were added for extraction, and the organic phase was washed with water and concentrated to dryness to give compound 20A, methyl 6-((6-bromo-1-fluoronaphthalen-2-yl)oxy)nicotinate, 1.2 g, yield: 77.0%. LCMS (ESI): C 17 H 11 Calculated value for BrFNO3. [M+H] + :376.0,Actual value:376.0.

[0131] [ka]

[0132] (b) For the following reaction scheme, compound 20A (200 mg, 0.53 mmol, 1 eq) was dissolved in dry THF (2 ml), then KOAc (104 mg, 1.06 mmol, 2 eq), Pd(dppf)2Cl2 (39 mg, 0.053 mmol, 0.1 eq), and bis(pinacolato)diboron (135 mg, 0.53 mmol, 1 eq) were added under N2, and the reaction mixture was heated to reflux for 2 h. After cooling, 10 ml of water and 10 ml of EtOAc were added for extraction, and the organic phase was washed with water and concentrated to dryness. The residue was purified by silica gel column chromatography (petroleum ether: EtOAc = 3: 1) to give compound 20B, methyl 6-((1-fluoro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-2-yl)oxy)nicotinate, 151 mg, yield: 67.1%. LCMS (ESI): C 23 H 23 Calculated for BFNO5; [M+H] + :424.2,Actual value:424.2.

[0133] [ka]

[0134] (c) For the following reaction scheme, compound 20B (100 mg) was dissolved in EtOH (2 ml), and then 30% H2O2 aqueous solution (1 ml) was added. The reaction mixture was stirred at room temperature for 1 h, quenched with saturated Na2SO3 aqueous solution, and extracted with EA. The organic phase was concentrated and purified by column (PE / EA=3 / 1) to give compound 20C (36 mg, yield: 37.0%). LCMS (ESI): 17 H 12 Calculated value for FNO4; [M+H] + :314.1,Actual value:314.1.

[0135] [ka]

[0136] (d) For the following reaction scheme, compound 20C (0.2 g, 0.47 mmol, 1 eq.), 1A-1 (0.1 g, 0.47 mmol, 1 eq.) and cesium carbonate (0.306 g, 0.94 mmol, 2 eq.) were dissolved in DMF (10 ml) for reaction. The reaction was carried out at 65° C. for 2 h. After cooling, 10 ml of water and 10 ml of EtOAc were added for extraction, and the organic phase was washed with water and concentrated to dryness to give compound 20D, 0.21 g, yield: 80.0%. LCMS (ESI): C 30 H 21 Calculated for Cl2FN2O5; [M+H] + :579.1,Actual value:579.1.

[0137] [ka]

[0138] (e) For the following reaction scheme, compound 20D (100 mg) was dissolved in dry THF (2 ml), then 10% NaOH aqueous solution (1 ml) was added under N2, and the reaction mixture was heated to reflux for 1 h. The pH of the reaction solution was adjusted to pH 3 to pH 4 by adding 1N HCl solution, and 10 ml of EA was added for extraction. The organic phase was concentrated and purified by column (PE / EA / AcOH=1 / 1 / 0.01 eluent) to give the title compound 20 (36 mg, yield: 37.0%).

[0139] [ka]

[0140] 1HNMR(400MHz,DMSO-d6)δ8.63(d,J=2.4Hz,1H),8.30(dd,J=8.7,2.4Hz,1H),7.92(d,J=9.0Hz,1H),7.70(s,1H),7.64(d,J=5.3 Hz,1H),7.60(d,J=6.4Hz,1H),7.57(d,J=4.3Hz,2H),7.42-7.36(m,2H),7.17(d,J=8.6Hz,1H),5.09(s,2H),1.22-1.06(m,5H). LCMS(ESI):C 29 H 19 Calculated for Cl2FN2O5. [M+H] + :565.1,Actual value:565.1.

[0141] [Example 21] Preparation of 6-((1-chloro-6-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)naphthalen-2-yl)oxy)nicotinic acid (compound 21)

[0142] [ka]

[0143] Following the procedure of Example 20, the title compound 21 was obtained by substituting 6-bromo-1-chloronaphthalen-2-ol for 20A-1. 1 HNMR(400MHz,DMSO-d6)δ8.63(s,1H),8.27(d,J=7.9Hz,1H),7.87-7.63(m,4H),7.60(s,1H),7.40-7.24 (m,2H),7.11(d,J=8.0Hz,1H),6.96(d,J=8.6Hz,1H),4.98(s,2H),2.47-2.40(m,1H),1.23-1.08(m,4H). LCMS(ESI):C 29 H 19 Calculated for Cl3N2O5; [M+H] + :581.0,Actual value:581.0.

[0144] [Example 22] Preparation of 6-((6-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)naphthalen-1-yl)oxy)nicotinic acid (compound 22)

[0145] [ka]

[0146] (a) For the following reaction scheme (Route D), compound 22A-1 (2.0 g, 12.49 mmol, 1 eq.), compound 22A-2 (1.71 g, 9.99 mmol, 0.8 eq.) and cesium carbonate (6.09 g, 18.74 mmol, 1.5 eq.) were dissolved in DMF (20 ml) for reaction. The reaction was carried out at 65° C. for 3 hours. After cooling, 30 ml of water and 30 ml of EA (ethyl acetate) were added for extraction, and the organic phase was washed with water and concentrated to dryness. The residue was purified by silica gel column chromatography (petroleum:AcOEt=5:1) to obtain compound 22A, methyl 6-((6-hydroxynaphthalen-1-yl)oxy)nicotinate, 1.1 g, yield: 37.3%. LCMS (ESI): C 17 H 13 Calculated for NO4; [M+H] + :296.1,Actual value:296.1.

[0147] [ka]

[0148] (b) For the following reaction scheme, compound 22A (0.2 g, 0.68 mmol, 1 eq.), 22A-3 (0.2 g, 0.68 mmol, 1 eq.) and cesium carbonate (0.44 g, 1.36 mmol, 2 eq.) were dissolved in DMF (5 ml) for reaction. The reaction was carried out at 40° C. for 2 hours. After cooling, 10 ml of water and 10 ml of EA were added for extraction, and the organic phase was washed with water and concentrated to dryness to obtain compound 22B, methyl 6-((6-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)naphthalen-1-yl)oxy)nicotinate, 0.31 g, yield: 81.2%. LCMS (ESI): C 30 H 22 Calculated for Cl2N2O5; [M+H] + :561.1,Actual value:561.1.

[0149] [ka]

[0150] (c) For the following reaction scheme, compound 22B (100 mg) was dissolved in methanol (2 ml), then 10% NaOH aqueous solution (1 ml) was added, the temperature was raised to 60° C., and the reaction was carried out for 0.5 hours. The pH of the reaction solution was adjusted from pH 2 to pH 4 by adding 1N HCl solution, and 10 ml of EA was added for extraction. The organic phase was concentrated with a column (PE / EA / AcOH=1 / 1 / 0.01 eluent) to obtain the title compound 22 (42 mg, yield: 43.2%).

[0151] 1 HNMR(400MHz,DMSO-d6)δ13.11(brs,1H),8.56(s,1H),8.28(d,J=8.5Hz,1H),7.66(dJ=8.3Hz,1H),7.56-7.61(m, 3H),7.45-7.53(m,2H),7.39(s,1H),7.15(t,J=9.6Hz,2H),6.9(d,J=9.2Hz,2H),4.98(s,2H),1.09-1.28(m,5H). LCMS(ESI):C 29 H 20Calculated for Cl2N2O5; [M+H] + :547.1,Actual value:547.1.

[0152] [ka]

[0153] [Example 23] Preparation of 6-((6-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)naphthalen-1-yl)oxy)picolinic acid (compound 23)

[0154] [ka]

[0155] Following the procedure of Example 22, the title compound 23 was obtained by substituting methyl 6-fluoropicolinate for 22A-2. 1 HNMR(400MHz,DMSO-d6)δ7.99(t,J=7.8Hz,1H),7.78(d,J=7.4Hz,1H),7.73(d,J=9.2Hz,1H),7.63(d,J=8.3Hz,1H),7.60-7.55(m,2H), 7.52-7.44(m,2H),7.40-7.37(m,1H),7.20(d,J=8.3Hz,1H),7.09(d,J=7.5Hz,1H),6.94-6.90(m,1H),4.99(s,2H),1.23-1.09(m,5H). LCMS(ESI):C 29 H 20 Calculated for Cl2N2O5; [M+H] + :547.1,Actual value:547.1.

[0156] [Example 24] Preparation of 2-((6-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)naphthalen-1-yl)oxy)isonicotinic acid (compound 24)

[0157] [ka]

[0158] Following the procedure of Example 22, the title compound 24 was obtained by substituting methyl 2-fluoroisonicotinate for 22A-2. 1 HNMR(400MHz,DMSO-d6)δ8.22(d,J=5.1Hz,1H),7.67-7.62(m,2H),7.58(d,J=8.0Hz,2H),7.53-7.42(m ,3H),7.38(s,2H),7.11(d,J=7.5Hz,1H),6.89(dd,J=9.2,2.4Hz,1H),4.98(s,2H),1.22-1.07(m,5H). LCMS(ESI):C 29 H 20 Calculated for Cl2N2O5; [M+H] + :547.1,Actual value:547.1.

[0159] [Example 25] Preparation of 3-((6-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)naphthalen-1-yl)oxy)picolinic acid (compound 25)

[0160] [ka]

[0161] Following the procedure of Example 22, the title compound 25 was obtained by substituting methyl 3-fluoropicolinate for 22A-2. 1 HNMR(400MHz,DMSO-d6)δ8.41-8.37(m,1H),7.90(d,J=9.2Hz,1H),7.62-7.54(m,3H),7.53-7.47(m,2H),7.4 3-7.35(m,2H),7.35-7.30(m,1H),6.99-6.94(m,1H),6.77(d,J=7.6Hz,1H),5.00(s,2H),1.21-1.10(m,5H). LCMS(ESI):C29 H 20 Calculated for Cl2N2O5; [M+H] + :547.1,Actual value:547.1.

[0162] [Example 26] Preparation of 2-((6-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)naphthalen-1-yl)oxy)-4-fluorobenzoic acid (compound 26)

[0163] [ka]

[0164] Following the procedure of Example 22, the title compound 26 was obtained by substituting methyl 2,4-difluorobenzoate for 22A-2. 1 HNMR(400MHz,DMSO-d6)δ8.22(d,J=5.1Hz,1H),7.67-7.61(m,2H),7.57(s,2H),7.52-7.4 3(m,3H),7.38(s,2H),7.11(d,J=7.5Hz,1H),6.90(s,0H),4.98(s,2H),1.20-1.06(m,5H). LCMS(ESI):C 30 H 20 Calculated for Cl2FNO5; [M+H] + :564.1,Actual value:564.1.

[0165] [Example 27] Preparation of 6-((6-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)naphthalen-1-yl)oxy)-2-methylnicotinic acid (compound 27)

[0166] [ka]

[0167] Following the procedure of Example 22, the title compound 27 was obtained by substituting methyl 6-chloro-2-methylnicotinate for 22A-2. 1 HNMR(400MHz,DMSO-d6)δ8.20(d,J=8.5Hz,1H),7.63(dd,J=8.8,4.5Hz,2H),7.57(s,1H),7.52-7.43(m,1H),7.38(d,J=2.7Hz ,1H),7.11(d,J=7.5Hz,1H),6.90(dd,J=9.2,2.5Hz,1H),6.81(d,J=8.6Hz,1H),4.98(s,2H),2.48(s,3H),1.23-1.00(m,5H). LCMS(ESI):C 30 H 22 Calculated for Cl2N2O5; [M+H] + :561.1,Actual value:561.1.

[0168] [Example 28] Preparation of 6-((6-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)naphthalen-1-yl)oxy)-5-methylnicotinic acid (compound 28)

[0169] [ka]

[0170] Following the procedure of Example 22, the title compound 28 was obtained by substituting methyl 6-chloro-5-methylnicotinate for 22A-2. 1 HNMR(400MHz,DMSO-d6)δ8.31(d,J=2.3Hz,1H),8.19(d,J=2.3Hz,1H),7.64(d,J=8.3Hz,1H),7.61-7.55(m,3H),7.53-7.44(m ,2H),7.38(d,J=2.7Hz,1H),7.11(d,J=7.5Hz,1H),6.88(dd,J=9.1,2.5Hz,1H),4.98(s,2H),2.47(s,3H),1.20-1.08(m,5H). LCMS(ESI):C 30 H22 Calculated for Cl2N2O5; [M+H] + :561.1,Actual value:561.1.

[0171] [Example 29] Preparation of 6-((5-chloro-6-((5-cyclopropyl-3-(2,6-dichlorophenyl)-isoxazol-4-yl)methoxy)naphthalen-2-yl)oxy)nicotinic acid (compound 29)

[0172] [ka]

[0173] Following the procedure of Example 32, the title compound 29 was obtained by substituting 6-bromo-1-chloronaphthalen-2-ol for 32A-1. 1 HNMR(400MHz,DMSO-d6)δ8.63(s,1H),8.29(d,J=8.6Hz,1H),7.92(d,J=8.9Hz,1H),7.70(s, 1H),7.65-7.46(m,4H),7.38(s,2H),7.17(d,J=8.5Hz,1H),5.09(s,2H),1.21-1.02(m,5H). LCMS(ESI):C 29 H 19 Calculated for Cl3N2O5: [M+H] + :581.0,Actual value:581.0.

[0174] [Example 30] Preparation of 6-((6-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)-2-fluoronaphthalen-1-yl)oxy)nicotinic acid (compound 30)

[0175] [ka]

[0176] Following the procedure of Example 20, the title compound 30 was obtained by substituting 6-bromo-2-fluoronaphthalen-1-ol for 20A-1. 1 HNMR(400MHz,DMSO-d6)δ8.59(d,J=2.4Hz,1H),8.31(dd,J=8.6,2.4Hz,1H),7.86(d,J=9.1Hz,1H),7.66(d,J=6.9Hz,1H),7.59(s,1H),7.56(dd,J= 5.7,3.3Hz,1H),7.51(dd,J=9.0,7.1Hz,1H),7.46-7.39(m,2H),7.25(d,J =8.6Hz,1H),7.05(dd,J=9.2,2.4Hz,1H),5.02(s,2H),1.28-1.08(m,5H). LCMS(ESI):C 29 H 19 Calculated for Cl2FN2O5; [M+H] + :565.1,Actual value:565.1.

[0177] [Example 31] Preparation of 6-((7-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)naphthalen-2-yl)oxy)nicotinic acid (compound 31)

[0178] [ka]

[0179] Following the procedure of Example 1, the title compound 31 was obtained by substituting naphthalene-2,7-diol for 1A-2. 1 HNMR(400MHz,DMSO-d6)δ8.64(s,1H),8.28(d,J=8.6Hz,1H),7.85(d,J=8.8Hz,1H),7.77(d,J=9.0Hz,1H),7.58(d,J=8. 1Hz,2H),7.55-7.43(m,2H),7.27(s,1H),7.13(t,J=9.9Hz,2H),6.89(d,J=8.9Hz,1H),4.95(s,2H),1.29-1.06(m,5H). LCMS(ESI):C29 H 20 Calculated for Cl2N2O5; [M+H] + :547.1,Actual value:547.1.

[0180] [Example 32] Preparation of 6-((6-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)-5-fluoronaphthalen-2-yl)oxy)nicotinic acid (compound 32)

[0181] [ka]

[0182] (a) For the following reaction scheme (Route B), compound 32A-1 (1.0 g, 4.15 mmol, 1 eq.), compound 1A-1 (1.44 g, 4.15 mmol, 1 eq.) and cesium carbonate (2.70 g, 8.30 mmol, 2 eq.) were dissolved in DMF (10 ml) for reaction. The reaction was carried out at 65° C. for 2 hours. After cooling, 10 ml of water and 10 ml of EA (ethyl acetate) were added for extraction, and the organic phase was washed with water and concentrated to dryness to obtain compound 32A, 4-(((6-bromo-1-fluoronaphthalen-2-yl)oxy)methyl)-5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazole, 1.51 g, yield: 71.9%. LCMS (ESI): C 23 H 15 Calculated for BrCl2FNO2; [M+H] + :506.0,Actual value:506.0.

[0183] [ka]

[0184] (b) For the following reaction scheme, compound 32A (200 mg, 0.39 mmol, 1 eq) was dissolved in dry THF (2 ml), then KOAc (76 mg, 0.78 mmol, 2 eq), Pd(dppf)2Cl2 (28 mg, 0.039 mmol, 0.1 eq), and bis(pinacolato)diboron (100 mg, 0.39 mmol, 1 eq) were added under N2, and the reaction mixture was heated to reflux for 2 h. After cooling, 10 ml of water and 10 ml of EA were added for extraction, and the organic phase was washed with water and concentrated to dryness. The residue was purified by silica gel column chromatography (petroleum:AcOEt=3:1) to give compound 32B, 5-cyclopropyl-3-(2,6-dichlorophenyl)-4-(((1-fluoro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-2-yl)oxy)methyl)isoxazole, 137 mg, yield: 62.8%. LCMS (ESI): C 29 H 27 Calculated for BCl2FNO4; [M+H] + :554.1,Actual value:554.1.

[0185] [ka]

[0186] (c) For the following reaction scheme, compound 32B (100 mg) was dissolved in EtOH (2 ml), and then 30% H2O2 aqueous solution (1 ml) was added. The reaction mixture was stirred at room temperature for 1 h, quenched with saturated Na2SO3 aqueous solution, and extracted with EA. The organic phase was concentrated and purified by column (PE / EA=3 / 1) to give compound 32C (61 mg, yield: 76.2%). LCMS (ESI): 23 H 16 Calculated for Cl2FNO3; [M+H] + :444.1,Actual value:444.1.

[0187] [ka]

[0188] (d) For the following reaction scheme, compound 32C (50 mg, 0.11 mmol, 1 eq.), 1A-3 (24.3 mg, 0.11 mmol, 1 eq.) and cesium carbonate (71.5 mg, 0.22 mmol, 2 eq.) were dissolved in DMF (1 ml) for reaction. The reaction was carried out at 65° C. for 2 h. After cooling, 5 ml of water and 5 ml of EA were added for extraction, and the organic phase was washed with water and concentrated to dryness to give compound 32D, 40 mg, yield: 61.5%. LCMS (ESI): 30 H 21 Calculated for Cl2FN2O5; [M+H] + :579.1,Actual value:579.1.

[0189] [ka]

[0190] (e) For the following reaction scheme, compound 32D (30 mg) was dissolved in MeOH (1 ml), then 10% NaOH aqueous solution (0.5 ml) was added under N2, and the reaction mixture was heated to reflux for 1 h. The pH of the reaction solution was adjusted to pH 3 to pH 4 by adding 1N HCl solution, and 5 ml of EA was added for extraction. The organic phase was concentrated and purified by column (PE / EA / AcOH=1 / 1 / 0.01 eluent) to give the title compound 32 (21 mg, yield: 71.7%).

[0191] 1 HNMR(400MHz,DMSO-d6)δ8.59(d,J=2.3Hz,1H),8.31(dd,J=8.6,2.4Hz,1H),7.86(d,J=9.1Hz,1H),7.62(d,J=5.3Hz,1H),7.59(s,1H),7.56(dd,J= 5.7,3.3Hz,1H),7.51(dd,J=9.0,7.1Hz,1H),7.46-7.40(m,2H),7.25(d,J =8.6Hz,1H),7.06(dd,J=5.7,4.3Hz,1H),5.02(s,2H),1.26-1.09(m,5H). LCMS(ESI):C 29 H 19Calculated for Cl2FN2O5; [M+H] + :565.1,Actual value:565.1.

[0192] [ka]

[0193] [Example 33] Preparation of sodium 6-((6-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)naphthalen-2-yl)oxy)nicotinate.

[0194] [ka]

[0195] An aqueous solution of NaOH (30%, 1.44 g, 1.2 eq) was added to a solution of compound 1 (4.99 g, 9.12 mmol) in EtOH at room temperature. The reaction mixture was heated to reflux for 6 h, after which the reaction mixture was cooled to room temperature. The solid was collected by filtration, washed with EtOH (10 ml), and dried to give a grey solid (4.07 g, yield: 78.3%).

[0196] [ka]

[0197] [Example 34] Preparation of calcium 6-((6-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)naphthalen-2-yl)oxy)nicotinate.

[0198] [ka]

[0199] To a solution of compound 35 (1.00 g, 1.76 mmol) in water (10 ml) was added a solution of CaCl2 (1.0 g, 20%) in water. A white precipitate formed. After the reaction mixture was stirred at room temperature for 4 h, the solid was collected by filtration and washed with water (2.0 ml) to give the product as a white solid (0.80 g, 76.7%).

[0200] [ka]

[0201] [Example 35] Preparation of 2-((6-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)naphthalen-1-yl)oxy)nicotinic acid

[0202] [ka]

[0203] The title compound 35 was prepared according to the procedure of Example 22, via Route D. 1 HNMR(400MHz,DMSO-d6)δ13.31(s,1H),8.29-8.24(m,1H),8.15-8.10(m,1H),7.67(d,J=9.1Hz,1H),7.64-7.56(m,3H),7.53-7.47(m,1H) ),7.47-7.42(m,1H),7.36(d,J=2.6Hz,1H),7.22-7.17(m,1H),7.06(d,J=7.4Hz,1H),6.92-6.87(m,1H),4.98(s,2H),1.24-1.08(m,5H). LCMS(ESI):C 29 H 20 Calculated for Cl2N2O5; [M+H] + :547.1,Actual value:547.1.

[0204] [Example 36] Preparation of 6-((5-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)naphthalen-2-yl)oxy)nicotinic acid

[0205] [ka]

[0206] The title compound 36 was prepared according to the procedure of Example 32, via Route B. 1 HNMR(400MHz,DMSO-d6)δ13.19(s,1H),8.65(d,J=2.4Hz,1H),8.29(dd,J=8.6,2.4Hz,1H),7.77(d,J=9.1Hz,1H),7.65-7.54(m,3H),7.51- 7.44(m,1H),7.44-7.34(m,2H),7.19(dd,J=9.2,2.4Hz,1H),7.14(d,J=8.7Hz,1H),7.01(d,J=7.4Hz,1H),5.09(s,2H),1.31-1.07(m,6H). LCMS(ESI):C 29 H 20 Calculated for Cl2N2O5; [M+H] + :547.1,Actual value:547.1.

[0207] [Example 37] Preparation of 6-((6-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)-5-fluoronaphthalen-2-yl)oxy)-2-methylnicotinic acid

[0208] [ka]

[0209] The title compound 37 was prepared according to the procedure of Example 32, via Route B. 1HNMR(400MHz,DMSO-d6)δ13.01(s,1H),8.24(d,J=8.6Hz,1H),7.91(d,J=9.1Hz,1H),7.68(s,1H),7.62(d,J=9.1Hz,1H),7.5 8(d,J=7.9Hz,2H),7.55-7.51(m,1H),7.43-7.34(m,2H),6.92(d,J=8.6Hz,1H),5.09(s,2H),2.52(s,3H),1.19-1.08(m,4H). LCMS(ESI):C 30 H 21 Calculated for Cl2FN2O5; [M+H] + :579.1,Actual value:579.1.

[0210] [Example 38] Preparation of 6-((7-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)-8-fluoronaphthalen-2-yl)oxy)nicotinic acid

[0211] [ka]

[0212] The title compound 38 was prepared according to the procedure of Example 32, via Route B. 1 HNMR(400MHz,DMSO-d6)δ8.64(s,1H),8.30(dd,J=8.7,2.4Hz,1H),7.96(d,J=8.9Hz,1H),7.70(d,J=9.0Hz,1H),7.64-7.48(m,3H), 7.37(t,J=8.8Hz,1H),7.27(d,J=9.2Hz,1H),7.19(d,J=8.6Hz,1H),6.85(s,1H),5.10(s,2H),2.07-1.89(m,1H),0.94-0.76(m,4H). LCMS(ESI):C 29 H 19 Calculated for Cl2FN2O5; [M+H] + :565.1,Actual value:565.1.

[0213] [Example 39] Preparation of 6-((6-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)-5-fluoronaphthalen-1-yl)oxy)-2-methylnicotinic acid

[0214] [ka]

[0215] The title compound 39 was prepared according to the procedure of Example 32, via Route B. 1 HNMR(400MHz,CDCl3)δ7.94(dd,J=7.9,5.0Hz,1H),7.83(d,J=8.1Hz,1H),7.72-7.59(m,2H),7.58-7.49(m,2H),7.49-7.38(m,2H),7.25 -6.97(m,1H),6.67(d,J=7.9Hz,1H),5.52(d,J=16.9Hz,1H),5.24(d,J=16.9Hz,1H),2.70-2.96(M,1H),2.61(s,3H),1.05-0.89(m,4H). LCMS(ESI):C 30 H 21 Calculated for Cl2FN2O5; [M+H] + :579.1,Actual value:579.1.

[0216] [Example 40] Preparation of 6-((6-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)naphthalen-1-yl)oxy)-5-methylpicolinic acid

[0217] [ka]

[0218] The title compound 40 was prepared according to the procedure of Example 22, via Route D. 1HNMR(400MHz,CDCl3)δ8.34(d,J=8.5Hz,1H),7.79(d,J=8.2Hz,1H),7.65-7.55(m,2H),7.54-7.49(m,2H),7.50- 7.40(m,2H),7.22(t,J=2.3Hz,1H),7.03-6.93(m,2H),5.44(s,2H),2.95-2.58(m,1H),2.22(s,3H),1.01(m,4H). LCMS(ESI):C 30 H 22 Calculated for Cl2N2O5; [M+H] + :561.1,Actual value:561.1.

[0219] [Example 41] Preparation of 6-((2,4-dichloro-6-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)naphthalen-1-yl)oxy)nicotinic acid

[0220] [ka]

[0221] The title compound 41 was prepared according to the procedure of Example 20, via Route C. 1 HNMR(400MHz,DMSO-d6)δ13.17(s,1H),8.66(d,J=2.4Hz,1H),8.34(dd,J=8.6,2.4Hz,1H),7.84-7.78(m,2H),7.70-7.65(m,2 H),7.64-7.56(m,2H),7.38(dd,J=9.1,2.3Hz,1H),7.24(d,J=8.6Hz,1H),4.92(s,2H),2.45-2.41(m,1H),1.22-1.10(m,4H). LCMS(ESI):C 29 H 18 Calculated for Cl4N2O5; [M+H] + :615.0,Actual value:615.0.

[0222] [Example 42] Preparation of 6-((2-chloro-6-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)naphthalen-1-yl)oxy)nicotinic acid

[0223] [ka]

[0224] The title compound 42 was prepared according to the procedure of Example 20, via Route C. 1 HNMR(400MHz,DMSO-d6)δ13.15(s,1H),8.65(d,J=2.4Hz,1H),8.31(dd,J=8 .6,2.4Hz,1H),7.76(d,J=2.4Hz,1H),7.70(d,J=8.8Hz,3H),7.66-7.59(m,1 H),7.51(d,J=8.8Hz,1H),7.44(d,J=9.1Hz,1H),7.22(dd,J=9.1,2.4Hz,1H ),7.19(d,J=8.6Hz,1H),4.87(s,2H),2.46-2.40(m,1H),1.30-1.09(m,4H). LCMS(ESI):C 29 H 19 Calculated for Cl3N2O5; [M+H] + :581.0,Actual value:581.0.

[0225] [Example 43] Preparation of 6-((1-chloro-6-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)naphthalen-2-yl)oxy)-2-methylnicotinic acid

[0226] [ka]

[0227] The title compound 43 was prepared according to the procedure of Example 20, following Route C. 1HNMR(400MHz,DMSO-d6)δ12.97(s,1H),8.24(d,J=8.6Hz,1H),8.00(d,J=9.2Hz,1H),7.80(d,J=8.9Hz,1H),7.60(d,J=8.0Hz,2H),7.55-7.49 (m,1H),7.47(s,1H),7.43(d,J=8.8Hz,1H),7.12(dd,J=9.2,2.5Hz,1H),6.95(d,J=8.6Hz,1H),5.02(s,2H),2.47(s,3H),1.23-1.11(m,5H). LCMS(ESI):C 30 H 21 Calculated for Cl3N2O5; [M+H] + :595.1,Actual value:595.1.

[0228] [Example 44] Preparation of 2-((6-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)-2-fluoronaphthalen-1-yl)oxy)-4-fluorobenzoic acid

[0229] [ka]

[0230] The title compound 44 was prepared according to the procedure of Example 20, via Route C. 1 HNMR(400MHz,DMSO-d6)δ13.04(s,1H),7.82(t,J=8.6Hz,1H),7.71(d,J=9.2 Hz,1H),7.57(d,J=7.8Hz,2H),7.52-7.46(m,1H),7.39(d,J=2.4Hz,1H),7.3 7-7.31(m,1H),7.15-7.10(m,1H),7.01(dd,J=9.3,2.4Hz,1H),6.88(dd,J=1 2.3,2.4Hz,1H),6.73(dd,J=8.7,2.3Hz,1H),5.08(s,2H),1.28-1.05(m,4H). LCMS(ESI):C 30 H 19 Calculated for Cl2F2NO5; [M+H] + :582.1,Actual value:582.1.

[0231] [Example 45] Preparation of 6-((6-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)-2-fluoronaphthalen-1-yl)oxy)-2-methylnicotinic acid

[0232] [ka]

[0233] The title compound 45 was prepared according to the procedure of Example 20, via Route C. 1 HNMR(400MHz,DMSO-d6)δ12.98(s,1H),8.21(d,J=8.6Hz,1H),7.65(dd,J=9.3,1.7Hz,1H),7.57(d,J=7.7Hz,2H),7.51-7.44(m,1H),7.37( d,J=2.5Hz,1H),7.35-7.29(m,1H),7.16-7.11(m,1H),6.98(dd,J=9.2,2.5Hz,1H),6.87(d,J=8.5Hz,1H),5.08(s,2H),1.22-1.09(m,4H). LCMS(ESI):C 30 H 21 Calculated for Cl2FN2O5; [M+H] + :579.1,Actual value:579.1.

[0234] [Example 46] Preparation of 6-((2-chloro-6-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)naphthalen-1-yl)oxy)-2-methylnicotinic acid

[0235] [ka]

[0236] The title compound 46 was prepared according to the procedure of Example 20, via Route C. 1HNMR(400MHz,DMSO-d6)δ13.03(s,1H),8.25(d,J=8.6Hz,1H),7.76(d,J=9.2H z,1H),7.69(d,J=8.2Hz,1H),7.58(d,J=8.0Hz,2H),7.50(d,J=8.1Hz,1H),7. 49-7.44(m,1H),7.18(d,J=8.2Hz,1H),7.04(dd,J=9.2,2.4Hz,1H),6.95(d,J =8.6Hz,1H),5.13(s,2H),2.59-2.54(m,1H),2.48(s,3H),1.27-1.15(m,4H). LCMS(ESI):C 30 H 21 Calculated for Cl3N2O5; [M+H] + :595.1,Actual value:595.1.

[0237] [Example 47] Preparation of 6-((6-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)-2-fluoronaphthalen-1-yl)oxy)-5-methylnicotinic acid

[0238] [ka]

[0239] The title compound 47 was prepared according to the procedure of Example 20, via Route C. 1 HNMR(400MHz,DMSO-d6)δ13.09(s,1H),8.32(s,1H),8.21(s,1H),7.67-7.55(m,3H),7.55-7.45(m,1H),7.39( s,1H),7.37-7.30(m,1H),7.20-7.09(m,1H),7.03-6.93(m,1H),5.09(s,2H),2.48(s,3H),1.41-1.00(m,5H). LCMS(ESI):C 30 H 21 Calculated for Cl2FN2O5; [M+H] + :579.1,Actual value:579.1.

[0240] [Example 48] Preparation of 2-((6-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)-2-fluoronaphthalen-1-yl)oxy)nicotinic acid

[0241] [ka]

[0242] The title compound 48 was prepared according to the procedure of Example 20, via Route C. 1 HNMR(400MHz,DMSO-d6)δ8.29-8.27(m,1H),8.22(d,J=8.5Hz,1H),8.09-8.06(m,1H),7.53-7.47(m,3H),7.46-7.42(m,1H) ,7.30-7.25(m,2H),7.08-7.05(m,1H),6.96(dd,J=8.4,2.4Hz,1H),5.44(s,2H),2.79(p,J=6.4Hz,1H),1.20-1.09(m,5H). LCMS(ESI):C 29 H 19 C l2 Calculated for FN2O5; [M+H] + :565.1,Actual value:565.1.

[0243] [Example 49] Preparation of 2-((6-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)-2-fluoronaphthalen-1-yl)oxy)-4-fluorobenzoic acid

[0244] [ka]

[0245] The title compound 49 was prepared according to the procedure of Example 22, via Route D. 1HNMR(400MHz,DMSO-d6)δ13.62(s,1H),7.84(d,J=9.2Hz,1H),7.63-7.55(m,3H),7.54-7.49(m,1H),7.42(t,J=7.9Hz,1H),7.40-7.32( m,2H),7.06(t,J=8.8Hz,1H),6.96(dd,J=9.1,2.5Hz,1H),6.90(d,J=7.5Hz,1H),6.56(d,J=8.4Hz,1H),4.99(s,2H),1.23-1.09(m,4H). LCMS(ESI):C 30 H 20 Calculated for Cl2FN2O5; [M+H] + :564.1,Actual value:564.1.

[0246] [Biological Examples] [Example A] FXR agonist binding capacity The activation effect of the compounds of the present invention on the binding of FXR to its co-stimulatory factor SRC-1 was evaluated by using a time-resolved analysis technique. The results are shown in Table 1.

[0247] Experimental materials 1. Protein: Glutathione-S-transferase (GST)-tagged human FXR protein (Invitrogen) 2. Coactivator: Fluorescein-labeled steroid receptor coactivator (SRC2-2) (Invitrogen) 3. Detection reagent: LanthaScreen time-resolved fluorescence assay kit (Invitrogen)

[0248] Experimental Method 1. Compounds were prepared as 10 mM stock solutions in DMSO and stored long term in a -20°C refrigerator. 2. Compounds are diluted to 1 mM prior to the experiment, then the compounds are diluted 3-fold with DMSO to give 10 concentration points. These 10 concentration points are then diluted 50-fold using Buffer G (Invitrogen, PV4553) to give the working fluids. 10 μl of each working solution is added to each well of a 384-well plate.

[0249] 3. Prepare a solution with human FXR protein (final concentration 20 nM) in chilled Buffer G and add 5 μl of human FXR protein solution to each well of a 384-well plate.

[0250] A mixture of 4.2 μM fluorescein-labeled steroid receptor coactivator and 20 n MGST antibody in buffer G is prepared. 5. Add 5 μl of the mixture prepared in step 4 to a 384-well plate.

[0251] 6. Centrifuge the 384 well plate at 1000g for 1 minute. 7. Incubate in the dark at room temperature for 1 hour. 8. Read the 384-well plate at 520 nm and 495 nm on an Envision 2104 plate reader. 9. EC in the activation effect of compounds 50 Calculate the value.

[0252] [Example B] FXR agonist transactivation ability The ability of the compounds of the present invention to promote FXR transactivation was evaluated by using luciferase reporter gene expression technology, and the results are shown in Table 1.

[0253] Experimental materials 1. Cell line: HEK293T (Invitrogen) 2. Expression plasmids: pBIND-hFXR-LBD-GAL4 (Promega), pGL4.35-Luciferase (Promega) 3. Cell culture medium: DMEM medium with 10% serum and penicillin / streptomycin double antibody 4. Detection reagent: Steady-Glo fluorescent detection system (Promega). 5. Transfection reagent: TransIT-293 transfection reagent (MIRUS BIO)

[0254] Experimental Method 1. Compounds were prepared as 10 mM stock solutions in DMSO and stored long term in a -20°C refrigerator.

[0255] 2. Resuscitation of HEK293T cells at 5.5 x 10 6 The cells were seeded onto a 10 cm culture dish at a concentration of 1:100 and incubated at 37° C. for 16 hours in a 5% CO 2 incubator.

[0256] 3. Before transfection, bring the transfection reagent to room temperature. Add Trans-IT solution dropwise to Opti-MEM and mix by inversion for 5 minutes; add expression plasmid, mix by inversion, and incubate at room temperature for 20 minutes.

[0257] 4. Add the transfection mixture from step 3 to the 10 cm dish prepared in step 2 and incubate for 5-6 hours in a 5% CO2 incubator.

[0258] 5. Dilute compounds 3-fold using DMSO to create 10 concentration points; add 25nl of compound per well to a 384-well plate using an Echo 550 sonic pipette; add HEK293T cells to the 384-well plate at a concentration of 15,000 cells / well; incubate at 37°C in a 5% CO2 incubator for 16-20 hours.

[0259] 6. Add 25 μl of Steady-Glo fluorescent reagent to each well and read fluorescence on an Envision 2104 plate reader.

[0260] 7. EC of compound activity 50 Calculate the value.

[0261] [Table 1-1]

[0262] [Table 1-2]

[0263] [Table 2-1]

[0264] [Table 2-2]

[0265] [Example C] Pharmacokinetic studies in mice Typical PK Study Procedure. For iv PK studies, groups of three fasted male CD-1 mice were dosed with compound (2.0 mg / kg, 0.50 mg / mL solution with 5% solutol in saline, clear solution) and 0.02 mL of blood was collected at 0.0830, 0.250, 0.500, 1.00, 2.00, 4.00, 8.00, and 24.0 hours. For PO PK studies, groups of three fasted male CD-1 mice were dosed with compound (10 mg / kg, 1 mg / mL solution with 5% solutol in saline, clear solution) and 0.02 mL of blood was collected at 0.250, 0.500, 1.00, 2.00, 4.00, 6.00, 8.00, and 24.0 hours. Blood was collected in EP tubes (containing 0.85-1.15 mg EDTA K2) and centrifuged at 3,000 g or 3,200 g for 10 min at 4°C, and plasma was isolated and divided into two vials; one was used for bioanalysis and the other was kept as a reserve. Samples were kept below -60°C until analyzed by LC MS / MS. Samples were analyzed using an AB SCIEX INSTRUMENTS LC-MS / MS_AU-Triple Quad 6500 Plus and data were processed using Phoenix WinNonlin 6.3 (IV-noncompartmental model and PO-noncompartmental model).

[0266] PK result The pharmacokinetic results in mice are shown in Table 3.

[0267] [Table 3]

[0268] [Example D] The therapeutic effects of FXR compounds were evaluated in a STZ+DEN+HFD-induced NASH model in male C57BL / 6 mice. Briefly, neonatal male C57BL / 6 mice were injected with streptozocin (STZ) at week 2 to induce diabetes and diethylnitrosamine (DEN) at week 4 to promote liver fibrosis. Mice that received neither STZ nor DEN were used as negative controls (group 1, n=12) and fed a normal diet. At week 6, 60 diabetic mice were selected (blood glucose level >12 mmol / L after 6 h fasting) and fed a high-fat diet (HFD, diet containing 60 kcal% fat). After 1 week on HFD, animals were randomly assigned into 5 groups based on body weight: Group 2 (n=12), disease model group, no compound treatment; Group 3 (n=10), positive control group, treated with OCA (30 mg / kg); Group 4 (n=12), treated with Compound 1 (3 mg / kg); Group 5 (n=12), treated with Compound 1 (10 mg / kg); Group 6 (n=12), treated with Compound 1 (30 mg / kg). OCA and Compound 1 were PO QD for 7 weeks. The day after the final dose, all animals were euthanized and liver tissues were fixed with formalin for pathological evaluation.

[0269] Figure 1 shows the reduction in NAS score after compound 1 treatment in STZ+DEN+HFD mouse disease model. Figure 2 shows the reduction in liver fibrosis after compound 1 treatment in STZ+DEN+HFD mouse disease model. As shown in Figure 1, compound 1 treatment at low dose (3 mg / kg), medium dose (10 mg / kg), and high dose (30 mg / kg) each showed a dose-dependent reduction in hepatocellular steatosis (p<0.001). The 30 mg / kg group showed a 46.2% reduction in NAS score compared to the model group. The positive control group (OCA 30 mg / kg) also showed a reduction in NAS score. As shown in Figure 2, compound 1 treatment at low dose (3 mg / kg) and high dose (30 mg / kg) significantly inhibited the progression of liver fibrosis, and the 30 mg / kg dose group reduced the rate of liver cirrhosis by 15.2%. In conclusion, after 7 weeks of treatment at 30 mg / kg per day, compound 1 significantly reduces NAS scores and liver fibrosis.

[0270] [Example E] The therapeutic effects of FXR compounds were evaluated in a DEN+HFD+CHOL-induced NASH model in male SD rats.

[0271] Neonatal male rats received DEN injections at postnatal week 2 to generate NASH models. Negative control animals (group 1, n=10) did not receive DEN injections. At week 4, 50 rats that received DEN injections started a HFD+CHOL diet (60kcal% fat + 1.25% cholesterol + 0.5% cholate) for 8 weeks, while the negative control animals were still on a normal diet. At week 5, the DEN-treated rats were randomly assigned into five groups (groups 2-6) based on body weight: disease group (group 2, n=10), received no treatment; OCA group (group 3, n=10) received OCA at 30mg / kg; groups 4-6 (n=10 each) received Compound 1 at low (3mg / kg), medium (3mg / kg), and high (3mg / kg) doses. OCA and Compound 1 were given PO QD for 7 weeks. The day after the final administration, all animals were euthanized and liver tissues were fixed with formalin for pathological evaluation.

[0272] Figure 3 shows the reduction in NAS scores in DEN+HFD+CHOL treated rats after treatment with Compound 1. Figure 4 shows the reduction in liver fibrosis in DEN+HFD+CHOL treated rats after treatment with Compound 1.

[0273] As shown in Figure 3, treatment with Compound 1 at low dose (3 mg / kg), medium dose (10 mg / kg), and high dose (30 mg / kg) showed a dose-dependent decrease in NAS score (all p<0.001). The NAS score of the 30 mg / kg group was reduced by 42.9% compared to the model group (Group 2). The positive control (OCA 30 mg / kg) also showed a decrease in NAS score (p<0.001). As shown in Figure 4, treatment with Compound 1 at low dose (3 mg / kg), medium dose (10 mg / kg), and high dose (30 mg / kg) significantly inhibited the progression of liver fibrosis (both p<0.01). Treatment with the 30 mg / kg group reduced the percentage of liver cirrhosis by 28.0%.

Claims

1. A compound for modulating the activity of FXR having the structure of formula (I), a pharma- ceutically acceptable salt thereof, or a stereoisomer thereof: 【Chemistry 1】 During the ceremony: R １ , R ２ and R ３ is H, halogen, unsubstituted or halogen-substituted C １～６ Alkyl, and unsubstituted or halogen substituted C １～６ alkoxy, where R １ , R ２ , and R ３ is not hydrogen; ０ is unsubstituted or halogen-substituted C １～６ Alkyl, C ３～６ Cycloalkyl and C ４～７ alkylcycloalkyl; X １ and X ２ is independently selected from H and halogen; The moiety -O-Z is attached to a naphthalene ring, where Z is a residue selected from a 5-10 membered aryl or a 5-10 membered heteroaryl optionally having one or more heteroatoms selected from N, O, and S, where said 5-10 membered aryl or 5-10 membered heteroaryl is selected from R ４ and optionally R ５ is further substituted by; Here, R ４ is -COOH, -CH ２ COOH, -NHSO ２ CF ３ , -SO ２ N.H.-C １～６ Alkyl, -SO ３ H, -CONHSO ２ -C １～６ Alkyl, -CONHSO ２ -C ３～６ Cycloalkyl, -CONHSO ２ -5 to 10 membered aryl and C in the aryl group １～６ -CONHSO substituted with alkyl ２ - selected from 5 to 10 membered aryl, where R ５ is H, C １～６ Alkyl, halogen, C １～６ Haloalkyl, —O—(C １～６ alkyl), and -NH-(C １～６ alkyl), A compound for modulating the activity of FXR having the structure of formula (I), a pharma- ceutically acceptable salt thereof, or a stereoisomer thereof.

2. R １ , R ２ and R ３ is H, halogen and C １～３ perfluoroalkoxy; R ０ The compound of claim 1 , wherein is selected from isopropyl or cyclopropyl.

3. R １ , R ２ and R ３ is H, Cl, F and -O-CF ３ 3. The compound of claim 2, independently selected from:

4. R １ and R ２ are Cl, and R ３ is H, F or -O-CH ３ or R １ is -O-CF ３ and R ２ and R ３ and R are H.

5. Z is R ４ and R ５ or Z is a 5-10 membered heteroaryl having one or more heteroatoms selected from N, O, and S, said 5-10 membered heteroaryl being selected from R ４ and optionally R ５ 2. The compound of claim 1 , substituted by:

6. Z is a 5-10 membered heteroaryl having one or more heteroatoms selected from N, O, and S, and said 5-10 membered heteroaryl is R ４ and optionally R ５ 6. The compound of claim 5 , substituted by:

7. Z is R ４ and optionally R ５ The compound of claim 1 which is a substituted pyridyl.

8. R ４ is -COOH, -CH ２ COOH, -CONHSO ２ -C １～６ Alkyl and -CONHSO ２ -C ３～６ 8. The compound of claim 1, wherein the aryl group is selected from cycloalkyl.

9. R ４ is -COOH or -CH ２ The compound of claim 8, which is COOH.

10. R ５ is H, C １～３ 2. The compound of claim 1, wherein the aryl group is selected from alkyl, alkyl, and halogen.

11. Z is pyridyl; R ４ is —COOH; and R ５ is H or a halogen.

12. The compound of claim 1 , wherein the halogen is fluoro or chloro.

13. The compound is 【Chemistry 2-1】 【Chemistry 2-2】 【Chemistry 2-3】 【Chemistry 2-4】 【Chemistry 2-5】 【Chemistry 2-6】 2. The compound of claim 1 selected from the group consisting of:

14. The compound has the following structure: 【Chemistry 3】 2. The compound of claim 1 having the formula:

15. The compound has the following structure: 【Chemistry 4】 2. The compound of claim 1 having the formula:

16. The compound has the following structure: 【Chemistry 5】 2. The compound of claim 1 having the formula:

17. The compound has the following structure: 【Chemistry 6】 2. The compound of claim 1 having the formula:

18. The compound has the following structure: 【Chemistry 7】 2. The compound of claim 1 having the formula:

19. The compound has the following structure: 【Chemistry 8】 2. The compound of claim 1 having the formula:

20. The compound has the following structure: 【Chemistry 9】 2. The compound of claim 1 having the formula:

21. The compound has the following structure: 【Chemistry 10】 2. The compound of claim 1 having the formula:

22. The compound has the following structure: 【Chemistry 11】 2. The compound of claim 1 having the formula:

23. 22. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1 to 21, or a pharma- ceutically acceptable salt thereof, or a stereoisomer thereof, and pharma- ceutically acceptable auxiliary materials.

24. 24. The pharmaceutical composition of claim 23, further comprising a second therapeutic agent useful for the treatment of non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis (PBC), cholestasis liver tree, chronic liver disease, hepatitis C infection, alcoholic liver disease, hepatic fibrosis, primary sclerosing cholangitis (PSC), gallstones, biliary atresia, lower urinary tract symptoms and benign prostatic hyperplasia (BPH), ureteral stones, obesity, type 2 diabetes, atherosclerosis, liver damage caused by atherosclerosis, hypercholesterolemia or dyslipidemia.

25. Use of a compound according to any one of claims 1 to 21, a pharma- ceutically acceptable salt thereof, or a stereoisomer thereof, or the pharmaceutical composition of claim 23 or claim 24, for the preparation of a medicament for treating a condition mediated by FXR in a patient.

26. 26. The use of claim 25, wherein the condition is non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis (PBC), cholestasis liver tree, chronic liver disease, hepatitis C infection, alcoholic liver disease, hepatic fibrosis, primary sclerosing cholangitis (PSC), gallstones, biliary atresia, lower urinary tract symptoms and benign prostatic hyperplasia (BPH), ureteral stones, obesity, type 2 diabetes, atherosclerosis, liver damage caused by atherosclerosis, hypercholesterolemia or dyslipidemia.

27. The compound of claim 9, wherein R 4 is —COOH.

Images